Company Profile
CEO
Mr. William H. Lewis J.D., M.B.A.(President, CEO & Chairman)
Sector
Healthcare
Industry
Biotechnology
Employees
1.7K
Beta
0.77
Forward P/E
270.2
52W High
$212.75
52W Low
$70.57
Profit Margin
-144.4%
Operating Margin
-65.5%
Return on Equity
-294.5%
Revenue Growth
229.6%
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical ...
Valuation
Market Cap$20.41B
P/E (TTM)--
P/S (TTM)16.68
EV/EBITDA--
Cash Flow
FCF Yield-4.4%
SBC Adj. FCF Yield-5.3%
SBC Impact20.2%
Margins & Growth
Profit Margin-53.5%
Operating Margin-50.1%
Revenue YoY229.6%
Earnings YoY--
Balance
Cash$582.19M
Debt$546.77M
Net Cash$35.42M
Dividend
Dividend Yield--
Payout Ratio--
Quarterly Payout--